Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.31 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL869529 | 1.00 | LMNA (0.39) | LMNAALDH1A1MAPTUSP2CYP3A4 | |
| SCHEMBL12252969 | 0.82 | CHRNB2 (0.47) | LMNAALDH1A1MAPTUSP2CYP3A4 | |
| SCHEMBL10186720 | 0.81 | CA1 (0.41) | CHRNB2CHRNB4CHRNA3CHRNA4APP | |
| SCHEMBL10150427 | 0.81 | PPARA (0.41) | LMNAALDH1A1MAPTCYP3A4RECQL | |
| SCHEMBL12143891 | 0.81 | CHRNB2 (0.32) | CHRNB2CHRNB4CHRNA3CHRNA4APP | |
| SCHEMBL13983710 | 0.79 | CHRNB2 (0.31) | CHRNB2CHRNB4CHRNA3CHRNA4APP | |
| SCHEMBL12619157 | 0.75 | CHRNB2 (0.35) | CHRNB2CHRNB4CHRNA3CHRNA4APP | |
| SCHEMBL9541336 | 0.75 | CHRNB2 (0.35) | CHRNB2CHRNB4CHRNA3CHRNA4APP | |
| SCHEMBL19900474 | 0.74 | PPARG (0.47) | LMNAMAPTUSP2CYP3A4RECQL | |
| SCHEMBL19418500 | 0.74 | CNR1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10239856-B2 | Synthesis of resorcylic acid lactones useful as therapeutic agents | UNIVERSITY DE STRASBOURG (FR) | 2019-03-26 | — | — | US | disclosed |
| EP-2136799-B1 | MACROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF KINASES AND HSP90 | UNIV STRASBOURG (FR) | 2017-10-04 | — | — | EP | disclosed |
| US-20170174669-A1 | POCHOXIME CONJUGATES USEFUL FOR THE TREATMENT OF HSP90 RELATED PATHOLOGIES | UNIV STRASBOURG (FR) | 2017-06-22 | — | — | US | disclosed |
| US-20170174669-A1 | POCHOXIME CONJUGATES USEFUL FOR THE TREATMENT OF HSP90 RELATED PATHOLOGIES | UNIV STRASBOURG (FR) | 2017-06-22 | — | — | US | disclosed |
| EP-2242359-B1 | SYNTHESIS OF RESORCYLIC ACID LACTONES USEFUL AS THERAPEUTIC AGENTS | UNIV STRASBOURG (FR) | 2016-06-01 | — | — | EP | disclosed |
| US-20160075677-A1 | SYNTHESIS OF RESORCYLIC ACID LACTONES USEFUL AS THERAPEUTIC AGENTS | UNIVERSITE DE STRASBOURG (FR) | 2016-03-17 | — | — | US | disclosed |
| US-20150374680-A1 | POCHOXIME CONJUGATES USEFUL FOR THE TREATMENT OF HSP90 RELATED PATHOLOGIES | UNIVERSITE DE STRASBOURG (FR) | 2015-12-31 | — | — | US | disclosed |
| US-20150374680-A1 | POCHOXIME CONJUGATES USEFUL FOR THE TREATMENT OF HSP90 RELATED PATHOLOGIES | UNIVERSITE DE STRASBOURG (FR) | 2015-12-31 | — | — | US | disclosed |
| US-9051302-B2 | Synthesis of resorcylic acid lactones useful as therapeutic agents | UNIVERSITE DE STRASBOURG (FR) | 2015-06-09 | — | — | US | disclosed |
| US-9051302-B2 | Synthesis of resorcylic acid lactones useful as therapeutic agents | UNIVERSITE DE STRASBOURG (FR) | 2015-06-09 | — | — | US | disclosed |
| US-8067412-B2 | analogs of natural products radicicol and pochonins; (oxirane or cyclopropan) 2-benzoxacyclo(di)tetradecin derivatives; inhibition of kinase phosphorylation activity and heat shock proteins; anticarcinogenic, antiinflammatory agent; neurodegenerative diseases; antiallergen | UNIVERSITE DE STRASBOURG (FR) | 2011-11-29 | — | — | US | disclosed |
| US-8067412-B2 | analogs of natural products radicicol and pochonins; (oxirane or cyclopropan) 2-benzoxacyclo(di)tetradecin derivatives; inhibition of kinase phosphorylation activity and heat shock proteins; anticarcinogenic, antiinflammatory agent; neurodegenerative diseases; antiallergen | UNIVERSITE DE STRASBOURG (FR) | 2011-11-29 | — | — | US | disclosed |
| US-20110217335-A1 | SYNTHESIS OF RESORCYLIC ACID LACTONES USEFUL AS THERAPEUTIC AGENTS | UNIVERSITE DE STRASBOURG (FR) | 2011-09-08 | — | — | US | disclosed |
| US-20110217335-A1 | SYNTHESIS OF RESORCYLIC ACID LACTONES USEFUL AS THERAPEUTIC AGENTS | UNIVERSITE DE STRASBOURG (FR) | 2011-09-08 | — | — | US | disclosed |
| US-20100292218-A1 | Treatment Of Neurofibromatosis With Radicicol And Its Derivatives | NEXGENIX PHARMACEUTICALS HOLDINGS, INC. | 2010-11-18 | — | — | US | disclosed |
| US-20100292218-A1 | Treatment Of Neurofibromatosis With Radicicol And Its Derivatives | NEXGENIX PHARMACEUTICALS HOLDINGS, INC. | 2010-11-18 | — | — | US | disclosed |
| WO-2009091921-A1 | SYNTHESIS OF RESORCYLIC ACID LACTONES USEFUL AS THERAPEUTIC AGENTS | UNIVERSITE DE STRASBOURG (FR) | 2009-07-23 | — | — | WO | disclosed |
| US-20080146545-A1 | Macrocyclic compounds useful as inhibitors of kinases and HSP90 | UNIVERSITE DE STRASBOURG (FR) | 2008-06-19 | — | — | US | disclosed |
| US-20080146545-A1 | Macrocyclic compounds useful as inhibitors of kinases and HSP90 | UNIVERSITE DE STRASBOURG (FR) | 2008-06-19 | — | — | US | disclosed |
| WO-2008021213-A1 | MACROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF KINASES AND HSP90 | WINSSINGER NICOLAS (FR) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174669-A1 | POCHOXIME CONJUGATES USEFUL FOR THE TREATMENT OF HSP90 RELATED PATHOLOGIES | HSP90AB2P, HSP90AB1, HSP90AA1 | LMNA 2869/4885ALDH1A1 2324/4885MAPT 1022/4885 |
| US-20150374680-A1 | POCHOXIME CONJUGATES USEFUL FOR THE TREATMENT OF HSP90 RELATED PATHOLOGIES | HSP90AB2P, HSP90AB1, HSP90AA1 | LMNA 2746/4885ALDH1A1 2726/4885MAPT 978/4885 |
| US-20100292218-A1 | Treatment Of Neurofibromatosis With Radicicol And Its Derivatives | HSP90AB2P, HSP90AA1, HSPA2 | LMNA 1203/4885ALDH1A1 1005/4885MAPT 2339/4885 |
| US-20110217335-A1 | SYNTHESIS OF RESORCYLIC ACID LACTONES USEFUL AS THERAPEUTIC AGENTS | HSP90AA1, HSP90AB1, HSP90AB2P | LMNA 2644/4885ALDH1A1 2526/4885MAPT 1374/4885 |
| US-10239856-B2 | Synthesis of resorcylic acid lactones useful as therapeutic agents | HSP90AA1, HSP90AB1, HSP90AB2P | LMNA 2644/4885ALDH1A1 2526/4885MAPT 1374/4885 |
| US-20080146545-A1 | Macrocyclic compounds useful as inhibitors of kinases and HSP90 | HSP90AB1, HSP90AA1, HSP90AB2P | LMNA 1828/4885ALDH1A1 3243/4885MAPT 1982/4885 |
| US-20160075677-A1 | SYNTHESIS OF RESORCYLIC ACID LACTONES USEFUL AS THERAPEUTIC AGENTS | HSP90AA1, HSP90AB1, HSP90AB2P | LMNA 2644/4885ALDH1A1 2526/4885MAPT 1374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.